Who are rosiglitazone and metformin combination tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pioglitazone + Metformin, rosiglitazone-metformin, Pioglitazone and Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosiglitazone-and-metformin-combination-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

rosiglitazone and metformin combination tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rosiglitazone and metformin combination tablet (rosiglitazone and metformin combination tablet) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione + Biguanide combination. Area: Diabetes.

phase 3 Thiazolidinedione + Biguanide combination PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

rosiglitazone and metformin combination tablet (rosiglitazone and metformin combination tablet) — Novo Nordisk A/S. Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rosiglitazone and metformin combination tablet TARGET	rosiglitazone and metformin combination tablet	Novo Nordisk A/S	phase 3	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
Pioglitazone + Metformin	Pioglitazone + Metformin	Sun Yat-sen University	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (pioglitazone); AMPK/mitochondrial complex I (metformin)
rosiglitazone-metformin	rosiglitazone-metformin	GlaxoSmithKline	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)
Pioglitazone and Metformin	Pioglitazone and Metformin	Takeda	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (pioglitazone); Complex I of mitochondrial respiratory chain (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione + Biguanide combination class)

GlaxoSmithKline · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rosiglitazone and metformin combination tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/rosiglitazone-and-metformin-combination-tablet. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab